Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Omeros Corporation

OMER

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

Last trade $13.71
Day change -$2.97 (-17.81%)
Day range $12.83 – $15.61
Volume 3,661,688
Market cap $1.21B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.21B
Price / earnings
9.67×
Price / book
-23.51×
Price / sales
31.43×
EV / sales
33.28×
EV / EBITDA
-17.78×

Profitability

Earnings per share
$1.72
Return on assets
43.52%
Return on equity
-243.09%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-1.43×
Current ratio
1.95×
Quick ratio
1.94×
Cash ratio
0.02×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$68.73M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for OMER, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$28.53M$9.89M$0$0$0$0$0$0
Cost of revenue$798K$587K$0$0$0$0$0$0
Gross profit$27.73M$9.31M$0$0$0$0$0$0
Selling, general and administrative$13.86M$13.37M$9.64M$10.4M$10.35M$11.12M$10.04M$11.32M
Research and development$13.8M$13.36M$19.45M$16M$22.01M$23.85M$23.32M$24.08M
Total operating expenses$27.66M$26.73M$29.08M$26.39M$32.35M$34.97M$33.36M$35.41M
Operating income$74K-$17.42M-$29.08M-$26.39M-$32.35M-$34.97M-$33.36M-$35.41M
Interest expense-$7.59M-$5.89M-$8.73M$13.36M-$15K-$3.65M-$3.18M-$4.05M
Income before taxes$6.67M$51.31M$81.9M-$21.24M-$25.89M-$37.57M-$34.24M-$37.11M
Income taxes$29K$57K$2.01M$0$0$0$2.31M$0
Net income$13.23M$56.06M$86.45M-$30.92M-$25.42M-$33.46M-$31.36M-$32.23M
Net income attributable to common shareholders$13.23M$56.06M$86.45M-$30.92M-$25.42M-$33.46M-$31.36M-$32.23M
EBITDA$267K-$17.18M-$28.85M-$26.15M-$32.15M-$34.68M-$33.05M-$35.17M
Basic earnings per share$0.18$0.78$1.22-$0.47-$0.43-$0.58-$0.54-$0.56
Diluted earnings per share$0.15$0.62$1.22-$0.47-$0.43-$0.58-$0.54-$0.56

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Omeros (OMER) Surpasses Q3 Earnings and Revenue Estimates

Omeros (OMER) reported quarterly earnings of $0.06 per share, beating consensus estimates by a loss of $0.05 and delivering a +220% earnings surprise. The company posted revenues of $35.93 million, surpassing estimates by 16.29%. Despite strong earnings performance, Omeros shares have underperformed the S&P 500 year-to-date, gaining 1.8% versus the market's 10.5% gain. The stock holds a Zacks Rank #2 (Buy) rating based on favorable estimate revisions.

GlobeNewswire Inc.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

Pomerantz LLP is investigating potential securities fraud claims against Omeros Corporation following the company's announcement on June 26, 2026, that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a negative opinion on the marketing authorization application for narsoplimab for treating TA-TMA. The negative regulatory decision triggered a 19.12% stock price decline, falling $2.05 per share to $8.67.

GlobeNewswire Inc.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER

Pomerantz LLP is investigating potential securities fraud claims against Omeros Corporation following the company's announcement of a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use on its marketing authorization application for narsoplimab. The news triggered a 19.12% stock price decline on June 26, 2026.

GlobeNewswire Inc.

Omeros Corporation Investigated by the Portnoy Law Firm

The Portnoy Law Firm has initiated an investigation into possible securities fraud at Omeros Corporation following the European Medicines Agency's negative opinion on the company's narsoplimab marketing authorization application on June 26, 2026. The negative regulatory decision triggered a 19.12% stock price decline, dropping from $10.72 to $8.67 per share. The firm is seeking to file a class action lawsuit on behalf of affected investors.

The Motley Fool

Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026?

Heartflow, an AI-driven diagnostic platform, shows strong 40% revenue growth but faces reimbursement headwinds and remains unprofitable. Omeros is transitioning to commercial stage with its newly approved drug Yartemlea, posting early Q1 2026 revenue of $9.89 million. The article recommends Omeros as the safer bet for 2026 despite trading at a premium, citing its transition to profitability versus Heartflow's expected positive free cash flow not until 2028.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.